The therapeutic effects of mesenchymal stem cell (MSCs) exosomes in covid-19 disease; Focusing on dexamethasone therapy.

Autor: Derafsh E; Department of Basic Medical Science, Windsor University School of Medicine, Brighton's Estate, Cayton, Saint Kitts and Nevis., Ebrahimzadeh F; Department of Internal Medicine, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, lran., Kahrizi MS; Alborz University of Medical Sciences, Karaj, Alborz, Iran., Kayedi M; Department of radiology. Shiraz university of medical sciences, Shiraz, iran., Shojaei N; School of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran., Rahimi S; School of medicine,fasa university of medical sciences,Fasa, Iran., Alesaeidi S; Department of Internal medicine and rheumatology, ⁎Rheumatology Research Center⁎, Tehran University of Medical Sciences, Tehran, Iran. Electronic address: S-alesaeidi@sina.tums.ac.ir., Ghafouri K; School of Medicine, Tehran University of Medical Sciences, Tehran, Iran. Electronic address: ghafouri.kim@gmail.com.
Jazyk: angličtina
Zdroj: Pathology, research and practice [Pathol Res Pract] 2023 Nov; Vol. 251, pp. 154815. Date of Electronic Publication: 2023 Sep 12.
DOI: 10.1016/j.prp.2023.154815
Abstrakt: The study of diseases, specifically their aetiologies, their step-by-step progressions (pathogenesis), and their impact on normal structure and function, is the focus of pathology, a branch of science and medicine. In therapeutic fields, it is critical to decrease significantly elevated levels of proinflammatory cytokines. The immunomodulatory drugs such as dexamethasone have been used in several of inflammatory diseases such as Covid-19. The use of dexamethasone alone or in combination with other drugs or method such as mesenchymal stem cell (MSC) is one of the most up-to-date discussions about Covid-19. In this review, we first examined the effects of dexamethasone as monotherapy on inflammatory cytokines and then examined studies that used combination therapy of dexamethasone and other drugs such as Baricitinib, Tofacitinib and tocilizumab. Also, therapeutic aspects of MSCs are examined in this review.
Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
(Copyright © 2023 Elsevier GmbH. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: